Top

News & Events

Client News

Client News

Morphoseq™ Novel DNA Sequencing Technology Enables Highly Accurate and Cost Effective Long Read Sequencing on Short Read NGS Platforms

Sydney, Australia – Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis in the Future’ meeting, May 21 – 23, Santa Fe, NM, USA, that enables long read sequencing on short read NGS platforms.

Read more »

HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reported recent business highlights and financial results for the first quarter ended March 31, 2019.

Read more »

Global Biotechnology and Venture Capital Executive Joins Imugene Board

SYDNEY, Australia – The Board of Imugene Limited today announced the appointment of leading biotechnology executive and entrepreneur Dr Jens Eckstein as a Non-Executive Director, effective 20 May 2019.

Read more »

Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

Maastricht, The Netherlands – Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced three upcoming poster presentations that highlight CPC634 positive data from its three phase 1 safety and biodistribution studies at the ASCO 2019 meeting, Chicago, Illinois May 31st - June 4th.

Read more »

Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology

Sydney, Australia  – Longas Technologies Pty Ltd (‘Longas’), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its Morphoseq™ technology and announcing the appointment to CEO of Nick McCooke, who built and led the team at Solexa that pioneered NGS prior to the company being acquired by Illumina.

Read more »

Civica Rx and Xellia Pharmaceuticals join forces to reduce chronic drug shortages

Lehi, UT and Buffalo Grove, IL - Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals today announced they have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s member health systems. Shortages of these anti-infective medications are impacting patient care in hospitals across the United States

Read more »

New tissue clearing kits and reagents for faster, accurate 3D imaging

Cambridge, UK – Abcam’s tissue clearing kits and reagents enable easy and rapid clearing for 3D imaging of tissues and cell culture models.

Read more »

HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”) for development of a therapeutic hepatitis B virus (HBV) vaccine. Based on the terms of the agreement, HOOKIPA is entitled to a milestone payment from Gilead.

Read more »

Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting

IRVINE, Calif. and BASEL, Switzerland – Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has announced that Dr. David Staskin presented positive, Phase 3 pivotal data demonstrating safety and efficacy of vibegron during a plenary session at the 2019 American Urological Association Annual Meeting (AUA) in Chicago on Sunday 5th May. Vibegron is an investigational novel, once-daily oral beta-3 adrenergic agonist being evaluated as a treatment for adults with symptoms of overactive bladder (OAB). Dr. Staskin, a leading urologist with St. Elizabeth’s Medical Center, and an Associate Professor of Urology at Tufts University School of Medicine in Boston, is a key investigator for vibegron.

Read more »

Confo Therapeutics raises €30 million in Series A financing

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The investment was led by BioGeneration Ventures (BGV) and co-led by Wellington Partners, with the addition of new investors Fund+ and Perceptive Advisors. Existing investors Capricorn Health-Tech Fund, Qbic, Participatie Maatschappij Vlaanderen NV (PMV), MINTS (University of Michigan), V-Bio Ventures and VIB also took part in the current financing round.

Read more »

Engitix Ltd Appoints Gino Van Heeke as Chief Scientific Officer

London, UK – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces the appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May.

Read more »

WISE enrols first patient in pivotal clinical study of novel neuro-electrodes for brain monitoring

Milan, Italy - WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring and neuromodulation, has enrolled its first patient in the pivotal clinical study of its WISE Cortical Strip.

Read more »

AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091

Geneva, Switzerland - AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128, with Boehringer Ingelheim’s anti-PD1 compound, BI754091, in Microsatellite Stable (MSS) patients with stage IV colorectal cancer.

Read more »

Clinigen appoints James Meyer as General Manager of Commercial Medicines in the US

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed James (‘Jim’) Meyer as General Manager, Commercial Medicines, US, with immediate effect.

Read more »

Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present preclinical data for an off-the-shelf CAR-NKT therapy platform at American Society of Gene & Cell Therapy 22nd Annual Meeting

HOUSTON and LONDON – Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest preclinical data generated as part of the development program for CMD-502, an off-the-shelf CAR-NKT therapy candidate for R/R CD19 expressing B-cell malignancies, at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C.1

Read more »

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

CAMBRIDGE, UK – Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect.

Read more »

Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present positive early patient data from CAR-NKT neuroblastoma trial at American Society of Gene & Cell Therapy 22nd Annual Meeting

HOUSTON and LONDON – Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that its collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest positive progress in the GINAKIT2 trial for children with R/R high risk neuroblastoma at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C.*

Read more »

Biotec Pharmacon Q1 2019 Results

Tromsø, Norway - Biotec Pharmacon (OSE: Biotec) announces its Q1 2019 results to 31 March 2019.

Read more »

Congenica Raises Additional £13.25M ($17.1M) to Reach Total of £23.3M ($30.1M) for Series B Funding Round

Cambridge, United Kingdom – Congenica, the global clinical decision support platform provider, today announced it has raised a further £13.25 ($17.1) million in additional equity investment, led by Parkwalk Advisors. The round attracted new strategic investors, including Digital China Health Technologies Corporation Limited (DCHealth), alongside follow-on funding from existing investors. The total amount raised across its B round financings is now £23.3 ($30.1) million.

Read more »

ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer

Basel, Switzerland - ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by BPI France, Schroder Adveq and the German High-Tech Gründerfonds (HTGF).

Read more »

National Care Group appoints James Allen as Chief Executive Officer

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, is delighted to announce the appointment of James Allen as Chief Executive Officer.

Read more »

HOOKIPA Appoints David R. Kaufman to its Board of Directors

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of David R. Kaufman, M.D., Ph.D., to its Board of Directors.

Read more »

Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia

London, UK – Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), today presented an update on its two Phase III SALAMANDER trials being conducted across Europe for its lead development programme REX-001 to treat CLI in patients with diabetes.

Read more »

Congenica Co-founder and Scientific Director Dr Matthew Hurles Elected to Fellowship of the Royal Society

Cambridge, United Kingdom – Congenica, the global diagnostic decision support platform provider, congratulates its co-founder and Scientific Director, Dr Matthew Hurles, FMedSci FRS, who has been elected to Fellowship of the Royal Society, the UK’s most prestigious scientific organisation.

Read more »

HOOKIPA Pharma Announces Pricing of Initial Public Offering

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share. In addition, HOOKIPA has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $84 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Read more »